Why Did GeoVax Labs Inc. (GOVX) Soar 10.34%?

On July 9, 2025, GeoVax Labs Inc. (GOVX:NASDAQ) experienced a significant surge in its stock price, rising by 10.34% in pre-market trading. This notable increase reflects the company's recent strategic moves and regulatory breakthroughs, which have bolstered investor confidence.

GeoVax Labs recently completed an equity capital raise, generating gross proceeds of approximately US$6 million in the early third quarter of 2025. This funding is expected to support the company's operations through the fourth quarter of 2025, providing a solid financial foundation for its ongoing projects.

The European Medicines Agency provided highly favorable guidance for GEO-MVA, GeoVax Labs' prophylactic vaccine for Mpox and smallpox. This regulatory approval allows the company to proceed directly to Phase 3 development, bypassing the need for Phase 1 and Phase 2 trials. This streamlined pathway not only accelerates the vaccine's development but also positions GeoVax Labs to engage with the World Health Organization's Prequalification process, unlocking access to global health procurement channels and funding support.

In addition to the regulatory breakthrough, GeoVax Labs has made significant clinical progress across its vaccine portfolio. GEO-CM04S1, a vaccine candidate, demonstrated dual protection capabilities against both SARS-CoV-2 and Mpox. Interim Phase 2 data showed that GEO-CM04S1 elicited a statistically superior cellular immune response in immunocompromised patients compared to Comirnaty, highlighting its potential in addressing critical health needs.

GeoVax Labs' strategic outlook remains robust, with a diversified vaccine portfolio addressing urgent global health needs. The company's pipeline includes Gedeptin, which completed a Phase 1/2a trial as monotherapy in advanced head and neck cancer and is expected to begin a Phase 2 trial as neoadjuvant therapy in 2026. The recent approval of Keytruda for resectable, locally advanced head and neck squamous cell carcinoma bodes well for Gedeptin's Phase 2 design, further enhancing the company's prospects.